| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/19/2006 | US20060013777 Novel treatment for cough |
| 01/19/2006 | US20060013776 Methods and compositions for treating benign gynecological disorders |
| 01/19/2006 | US20060013775 Use of ppar activators for the treatment of pulmonary fibrosis |
| 01/19/2006 | US20060013770 Method for screening for compounds as potential sedatives or anxiolytics |
| 01/19/2006 | US20060011891 Nadh/nadph-containing compound |
| 01/19/2006 | DE60110592T2 Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer A pharmaceutical composition comprising a farnesyl transferase inhibitory 1,2-annelated quinoline enantiomer |
| 01/19/2006 | DE102004063363A1 Composition for treatment and prevention of bronchial disease or allergy and for strengthening immune system, contains capsaicin or its derivatives |
| 01/19/2006 | DE102004032263A1 New 7-butynyl-8-(3-amino-1-piperidinyl)xanthine derivatives useful as dipeptidyl peptidase IV inhibitors, e.g. for treating diabetes, arthritis, obesity and osteoporosis |
| 01/19/2006 | DE102004032103A1 Gegen Missbrauch gesicherte, orale Darreichungsform Abuse-proofed oral dosage form |
| 01/19/2006 | DE102004031656A1 Tetrahydrochinoline Tetrahydroquinolines |
| 01/19/2006 | DE102004027353A1 Use of tamsulosin hydrochloride for treating hemorrhoids and benign blood blisters in the anus |
| 01/19/2006 | DE102004016779A1 Drospirenonhaltige Zubereitungen zur transdermalen Anwendung Drospirenonhaltige formulations for transdermal application |
| 01/19/2006 | CA2581674A1 Indoleamine 2,3-dioxygenase (ido) inhibitors |
| 01/19/2006 | CA2574437A1 Infusion and injection solution of levodopa |
| 01/19/2006 | CA2573927A1 Porphyrin linked metronidazole against gum disease: porphyromonas gingivalis |
| 01/19/2006 | CA2573662A1 Pharmaceutical composition of piperazine derivatives |
| 01/19/2006 | CA2573611A1 Agent for promoting the recovery from dysfunction after the onset of central neurological disease |
| 01/19/2006 | CA2573609A1 Porphyrin derivatives and their use in photon activation therapy |
| 01/19/2006 | CA2573604A1 Novel 2,6-diaminopyridine-3-one derivatives |
| 01/19/2006 | CA2573603A1 Novel 2,4-diaminothiazol-5-one derivatives |
| 01/19/2006 | CA2573596A1 S100 protein inhibitors for treating leukemia |
| 01/19/2006 | CA2573481A1 Method of evaluating evenness of suplatast tosilate crystal, even crystal, and process for producing the same |
| 01/19/2006 | CA2573396A1 Improved process for the preparation of oxidized phospholipids |
| 01/19/2006 | CA2573380A1 Amide derivatives as inhibitors of histone deacetylase |
| 01/19/2006 | CA2573378A1 Amide derivatives as inhibitors of histone deacetylase |
| 01/19/2006 | CA2573372A1 Sulfonamide derivatives |
| 01/19/2006 | CA2573261A1 Compositions for enhancing the production of ppar and/or ppar-associated factors |
| 01/19/2006 | CA2573209A1 Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors |
| 01/19/2006 | CA2573176A1 Nup98-hox fusions for expansion of hemopoietic stem cells |
| 01/19/2006 | CA2573092A1 Pyridodihydropyrazinones method for production and use thereof as medicaments |
| 01/19/2006 | CA2573072A1 Use of ecteinascidin in the treatment of cancer in patients with low level of brca1 |
| 01/19/2006 | CA2572982A1 Treatment of age-related memory impairment using phosphate-glycerol carrying bodies |
| 01/19/2006 | CA2572815A1 Combination therapies employing nicotinic acid derivatives or fibric acid derivatives |
| 01/19/2006 | CA2572551A1 Combination of anti-hiv reverse transcriptase and protease inhibitors |
| 01/19/2006 | CA2572344A1 Compositions and methods for treating eye disorders and conditions |
| 01/19/2006 | CA2572179A1 Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| 01/19/2006 | CA2571824A1 Mitotic kinesin inhibitors |
| 01/19/2006 | CA2571821A1 Prodrugs of mitotic kinesin inhibitors |
| 01/19/2006 | CA2571807A1 Mitotic kinesin inhibitors |
| 01/19/2006 | CA2571756A1 2, 4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
| 01/19/2006 | CA2571750A1 2, 4, 6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
| 01/19/2006 | CA2571748A1 2, 4, 6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
| 01/19/2006 | CA2571589A1 Compounds and methods for treating diabetic vascular diseases |
| 01/19/2006 | CA2571572A1 Mitotic kinesin inhibitors |
| 01/19/2006 | CA2571554A1 A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device |
| 01/19/2006 | CA2571178A1 2-substituted heteroaryl compounds |
| 01/19/2006 | CA2570920A1 Piperidine derivatives as renin inhibitors |
| 01/19/2006 | CA2570918A1 Use of phenylethanolaminotetralines for preparing anxiolytic drugs |
| 01/19/2006 | CA2570853A1 Abnormal cannabidiols for lowering intraocular pressure |
| 01/19/2006 | CA2570614A1 Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
| 01/19/2006 | CA2570591A1 Antibiotics containing borinic acid complexes and methods of use |
| 01/19/2006 | CA2570524A1 High ibuprofen content granules and their preparation and their use in pharmaceutical dosage forms |
| 01/19/2006 | CA2570518A1 Tetracyclic compounds as estrogen ligands |
| 01/19/2006 | CA2570419A1 Compositions of stable bioactive metabolites of docosahexaenoic (dha) and eicosapentaenoic (epa) acids |
| 01/19/2006 | CA2570155A1 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nachr ligands for the treatment of cns diseases |
| 01/19/2006 | CA2570153A1 Granules for controlled release of tamsulosin |
| 01/19/2006 | CA2570096A1 Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one |
| 01/19/2006 | CA2569888A1 Use of l-carnitine for the treatment of cardiovascular diseases |
| 01/19/2006 | CA2569091A1 Modulation of gsk-3.beta. and method of treating proliferative disorders |
| 01/19/2006 | CA2568993A1 S-tenatoprazole sodium monohydrate salt and the use thereof in the form of a proton pump inhibitor |
| 01/19/2006 | CA2567808A1 Therapy of platinum-resistant cancer |
| 01/19/2006 | CA2567742A1 Spray composition comprising a combination of calcitriol and clobetasol propionate, an alcoholic phase, at least one volatile silicone and one non volatile oily phase |
| 01/19/2006 | CA2567687A1 Pressurized foaming composition for topical treatment of psoriasis |
| 01/19/2006 | CA2567682A1 Invert emulsion composition containing calcitriol and clobetasol 17-propionate, and uses thereof in cosmetics and dermatology |
| 01/19/2006 | CA2567680A1 Pharmaceutical composition comprising an ointment and two solubilized active principles |
| 01/18/2006 | EP1617219A1 Element having bioactive substance fixed thereto |
| 01/18/2006 | EP1617218A1 METHOD OF SCREENING DRUG WITH THE USE OF 67 kDa LAMININ RECEPTOR AND DRUG OBTAINED THEREBY |
| 01/18/2006 | EP1616957A1 Vector |
| 01/18/2006 | EP1616883A2 Antibodies against VLA-4 |
| 01/18/2006 | EP1616878A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/18/2006 | EP1616874A1 Mono- and bicyclic compounds with therapeutic activity and pharmaceutical compositions including them |
| 01/18/2006 | EP1616873A1 Lipid-regulating agent and use thereof |
| 01/18/2006 | EP1616871A1 Porphyrin compound containing biotinyl group and use thereof |
| 01/18/2006 | EP1616869A1 Substituted porphyrins and their therapeutic use |
| 01/18/2006 | EP1616867A1 Hydroxycarboxylic acid derivatives |
| 01/18/2006 | EP1616866A1 M-stage kinesin inhibitor |
| 01/18/2006 | EP1616865A1 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| 01/18/2006 | EP1616862A1 Nitrogenous heterocyclic compound and use thereof |
| 01/18/2006 | EP1616861A2 A process for the preparation of keto compounds |
| 01/18/2006 | EP1616859A1 Substituted cyclohexyl carboxylic acid compounds |
| 01/18/2006 | EP1616856A1 Novel transcriptional factor, process for producing the same and use thereof |
| 01/18/2006 | EP1616577A1 Agent for repairing corneal perception |
| 01/18/2006 | EP1616576A1 Specific nad(p)h oxidase inhibitor |
| 01/18/2006 | EP1616572A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody |
| 01/18/2006 | EP1616570A1 Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood |
| 01/18/2006 | EP1616569A1 Medicinal composition |
| 01/18/2006 | EP1616568A2 GSK-3 inhibitors and CDK inhibitors as anti-glaucoma agents |
| 01/18/2006 | EP1616567A1 Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| 01/18/2006 | EP1616566A1 Lipoxin compounds for treating TNF-alpha initiated inflammation |
| 01/18/2006 | EP1616565A1 Composition for relieving unpleasant symptoms accompanying change in protesterone |
| 01/18/2006 | EP1616564A2 Manipulation of nitrosative stress for treating microbes and helminths |
| 01/18/2006 | EP1616563A2 Perivascular administration of anti-angiogenic factors for treating or preventing vascular diseases |
| 01/18/2006 | EP1616562A1 Novel preparation and administration form comprising an acid-labile active compound |
| 01/18/2006 | EP1616561A1 Antidiabetic preparation for oral administration |
| 01/18/2006 | EP1616556A1 Compostions comprising gelatin-glycine and carotenoids |
| 01/18/2006 | EP1616490A1 Composition comprising lutein, zinc and copper |
| 01/18/2006 | EP1616184A2 A method and kit for detecting the early onset of renal tubular cell injury |
| 01/18/2006 | EP1616005A1 Di-glycosyl-glyceryl compounds for the stabilisation and preservation of biomaterials |
| 01/18/2006 | EP1615959A2 A method for the production of emulsion-based micro particles |
| 01/18/2006 | EP1615952A2 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2 |